Payment overview · 2025
General Payments
$594.06
37 reported records · 14 companies
Healthcare provider profile · identity verified
Sherry Sweikert-Smith
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · LEWISTON, ID · NPI 1831676048
Verified facts
What the public records show
CMS Open Payments records show Sherry Sweikert-Smith received $594.06 in general payments during 2025 across 37 reported records.
GlaxoSmithKline, LLC. accounted for 24.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $144.55 | 24.3% | 16 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $66.32 | 11.2% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $51.71 | 8.7% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $49.92 | 8.4% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $48.12 | 8.1% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $46.11 | 7.8% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $36.08 | 6.1% | 2 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $32.39 | 5.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.56 | 4.8% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $25.02 | 4.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.91 | 3.2% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $17.20 | 2.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.85 | 2.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.32 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $594.06 | 37 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $144.55 | 16 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $66.32 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $51.71 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $51.71 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $49.92 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $36.08 | 2 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $32.39 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $29.17 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $28.56 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $25.02 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $24.89 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $21.22 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.95 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.95 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $18.91 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.91 | 1 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $17.20 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $14.85 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.32 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 77 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 64 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
64 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
77 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
68 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 447 | 126 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 288 | 62 |
| Omeprazole | Omeprazole | 264 | 67 |
| Atorvastatin Calcium | Atorvastatin Calcium | 252 | 70 |
| Losartan Potassium | Losartan Potassium | 237 | 62 |
| Gabapentin | Gabapentin | 168 | 37 |
| Amlodipine Besylate | Amlodipine Besylate | 166 | 44 |
| Sertraline Hcl | Sertraline Hcl | 138 | 26 |
| Lisinopril | Lisinopril | 133 | 42 |
| Lorazepam | Lorazepam | 113 | 22 |
| Metformin Hcl Er | Metformin Hcl | 103 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 100 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 98 | 28 |
| Tramadol Hcl | Tramadol Hcl | 98 | 20 |
| Montelukast Sodium | Montelukast Sodium | 97 | 24 |
| Simvastatin | Simvastatin | 94 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 92 | 19 |
| Methocarbamol | Methocarbamol | 87 | 22 |
| Trazodone Hcl | Trazodone Hcl | 86 | 19 |
| Allopurinol | Allopurinol | 82 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 81 | 19 |
| Alendronate Sodium | Alendronate Sodium | 78 | 21 |
| Ozempic | Semaglutide | 77 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 75 | 16 |
| Potassium Chloride | Potassium Chloride | 75 | 22 |
| Metformin Hcl | Metformin Hcl | 73 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 70 | 29 |
| Eliquis | Apixaban | 68 | suppressed |
| Furosemide | Furosemide | 64 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 64 | 12 |
| Pantoprazole Sodium | Pantoprazole Sodium | 61 | 20 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 60 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 60 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 58 | suppressed |
| Alprazolam | Alprazolam | 56 | 15 |
| Pregabalin | Pregabalin | 56 | suppressed |
| Estradiol | Estradiol | 49 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 48 | 14 |
| Tamsulosin Hcl | Tamsulosin Hcl | 47 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 46 | 15 |
| Glimepiride | Glimepiride | 46 | suppressed |
| Fenofibrate | Fenofibrate | 45 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 45 | 13 |
| Bupropion Xl | Bupropion Hcl | 44 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 44 | suppressed |
| Ezetimibe | Ezetimibe | 40 | suppressed |
| Glipizide | Glipizide | 40 | suppressed |
| Lovastatin | Lovastatin | 40 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 39 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 39 | suppressed |
| Prednisone | Prednisone | 39 | 26 |
| Spironolactone | Spironolactone | 39 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 38 | 15 |
| Jardiance | Empagliflozin | 37 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 37 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 36 | suppressed |
| Carvedilol | Carvedilol | 35 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 34 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 33 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | suppressed |
| Baclofen | Baclofen | 31 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 31 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 30 | 13 |
| Celecoxib | Celecoxib | 29 | suppressed |
| Glipizide Er | Glipizide | 29 | suppressed |
| Famotidine | Famotidine | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Valsartan | Valsartan | 27 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 26 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 26 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 23 | suppressed |
| Mounjaro | Tirzepatide | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Fluconazole | Fluconazole | 22 | 11 |
| Meloxicam | Meloxicam | 22 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 19 | suppressed |
| Telmisartan | Telmisartan | 19 | suppressed |
| Mupirocin | Mupirocin | 18 | 16 |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 16 |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | 13 |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 16 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Azithromycin | Azithromycin | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | 14 |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 12 |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 11 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Movantik | Naloxegol Oxalate | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $594.06 · 37 records | GlaxoSmithKline, LLC. | AIRSUPRA, AUSTEDO XR, CAPLYTA, Cologuard Collection Kit, GEMTESA, JARDIANCE, NEXPLANON, NURTEC ODT, Omnipod, Ozempic, QULIPTA, REXULTI, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, Wegovy, ZAVZPRET | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error